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Dacarbazine Promotes Stromal Remodeling and
Lymphocyte Infiltration in Cutaneous Melanoma
Lesions
Alessandra Nardin1, Wing-Cheong Wong2, Charlene Tow1, Thierry Jo Molina3,8, Fre´de´rique Tissier4,5,6,8,
Anne Audebourg4, Marylene Garcette5,6, Anne Caignard5,6, Marie-Francoise Avril5,6,7, Jean-Pierre
Abastado1,9 and Armelle Pre´vost-Blondel5,6,9
Dacarbazine (DTIC) is the standard first-line drug for advanced stage melanoma, but it induces objective clinical
responses in only 15% of patients. This study was designed to identify molecular changes specifically induced
by treatment in chemo-sensitive lesions. Using global transcriptome analysis and immunohistochemistry,
we analyzed cutaneous metastases resected from patients with melanoma before and after DTIC treatment. The
treatment induced similar functional changes in different lesions from the same patient. Stromal and immune
response-related genes were the most frequently upregulated, particularly in lesions that responded to
treatment by stabilizing or regressing. T-cell infiltration and enhanced major histocompatibility complex class II
expression were observed in a subset of patients. Stable, chemo-sensitive lesions exhibited activation of genetic
programs related to extracellular matrix remodeling, including increased expression of secreted protein acidic
and rich in cysteine (SPARC) by tumor cells. These events were associated with local response to treatment and
with superior survival in our group of patients. In contrast, SPARC expression was downregulated in lesions resistant
to DTIC. Thus, chemotherapy drugs originally selected for their direct cytotoxicity to tumor cells may also influence
disease progression by inducing changes in the tumor microenvironment.
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INTRODUCTION
Malignant melanoma is one of the deadliest types of skin
cancer. Although it can be effectively managed and often
cured in its early stages by resection, metastatic melanoma is
often resistant to chemotherapy and has a very poor prognosis,
with a median survival time of 6 months (Gray-Schopfer et al.,
2007). The standard first-line treatment, dacarbazine (DTIC),
produces objective responses in 15% of patients and offers
limited survival benefit (Bhatia et al., 2009).
Chemotherapy drugs such as DTIC, originally selected for
their direct toxicity to tumor cells, could also indirectly
promote tumor killing by effector components of the immune
system, such as T cells or antibodies (Demaria et al., 2001;
Emens et al., 2001; Machiels et al., 2001; Yang and Haluska,
2004; Menard et al., 2008; Zitvogel et al., 2008). These
observations suggest that improved patient outcomes might
be achieved using rational combinations of chemotherapy
and immunotherapies. However, at present, the understand-
ing of the influence of chemotherapeutic agents on the tumor
immune microenvironment is still limited. In particular, the
molecular events induced by DTIC treatment in chemo-
sensitive or chemo-resistant melanoma lesions have not been
characterized.
The aim of this project was to determine how DTIC
treatment modifies the melanoma tumor microenvironment,
and whether these changes are associated with a clinical
benefit. Cutaneous metastases were resected from patients
before and after DTIC treatment; in some patients, several
post-treatment lesions were analyzed to understand the
consistency of tumor response within an individual. Specific
treatment-induced modifications of gene expression were
defined by statistical analysis. We identified a set of genes
that are modulated by chemotherapy, over and above normal
biological inter-tumor variability. Biological processes
related to stromal remodeling and lymphocyte infiltration/
activation are predominantly upregulated in chemo-sensitive
lesions, and are associated with superior patient survival.
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RESULTS
Chemotherapy modulates both immune and stromal
components of melanoma lesions
To identify genes specifically modulated by chemotherapy in
melanoma lesions, we resected and analyzed 13 pre-treat-
ment and 20 matched post-treatment samples obtained from
a total of 13 melanoma patients. Clinical and demographic
characteristics of patients are shown in Table 1. The vari-
ability and kinetics of chemotherapy-induced changes were
assessed in some patients by collecting several lesions (2–3)
at different time points during the course of treatment.
To identify tumor responses due to chemotherapy, we
compared gene expression changes between the pre- and the
post-treatment samples acquired from each single patient
Table 1. Patient demographics and clinical characteristics
Patient
code Gender
Age
(years)
Stage at
inclusion
Survival
(months)1
Sample
code
Year of
excision
Chemotherapy/
no. of cycles
Response
lesion
Response
patient
Pt1 M 61 III 27.5 Pre-1 October 2006 NA NA NA
1-12 February 2007 DTIC/4 Regression PR
1-22 Regression
1-3 July 2007 DTIC/8 Stable PR
Pt2 M 77 III 183 Pre-2 February 2008 NA NA NA
2-1 April 2008 DTIC/1 Regression PR
2-2 April 2008 DTIC/2 Regression CR
Pt3 F 59 III 445 Pre-3 November 2006 NA NA NA
3-1 January 2007 DTIC/2 Stable PD
3-2 February 2007 DTIC/3 Stable SD
3-3 May 2007 DTIC/5 Stable PR
Pt4 M 79 III 6.5 Pre-4 March 2008 NA NA NA
4 May 2008 DTIC/2 Progression PD
Pt5 F 75 IV M1a 19.5 Pre-5 March 2007 NA NA NA
5-1 June 2007 DTIC/3 Stable SD
5-2 November 2007 DTIC/6 Progression PD
Pt6 M 78 IV M1a 3 Pre-6 September 2008 NA NA NA
6-1 November 2008 DTIC/2 Progression PD
Pt7 M 66 IV M1a 3 Pre-7 November 2008 NA NA NA
7-1 January 2009 DTIC/2 Progression PD
Pt8 M 80 IV M1b 14 Pre-8 August 2007 NA NA NA
8-1 December 2007 DTIC/3 Stable PD
8-2 June 2008 Fotemustine Progression PD
Pt9 M 79 IV M1c 4 Pre-9 January 2009 NA NA NA
9-1 March 2009 DTIC/2 Progression PD
Pt104 F 46 IV M1c 5.5 Pre-10 April 2008 NA NA NA
10-1 May 2008 DTIC/1.5 Stable PD
Pt11 M 24 IV M1c 2 Pre-11 March 2006 NA NA NA
11-1 May 2006 DTIC/2 Progression PD
Pt12 M 53 IV M1c 2 Pre-12 January 2008 NA NA NA
12-1 March 2008 DTIC/2 Progression PD
Pt13 M 34 IV M1c 6.5 Pre-13 January 2009 NA NA NA
13-1 March 2009 DTIC/2 Progression PD
Abbreviations: CR, complete response; DTIC, dacarbazine; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease.
1Survival months from first day of chemotherapy.
2Two different skin lesions were collected on the same day.
3Cause of death: colon cancer.
4Primary uveal melanoma. Primary melanoma was cutaneous in all other patients.
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with changes across the various pre-treatment samples
(reflecting the biological variability between tumors). This
generated a list of gene probes that were more affected
by chemotherapy than by inter-patient variability, and thus
considered chemotherapy specific.
Upon unsupervised hierarchical clustering of all chemo-
therapy-specific gene probes, multiple post-treatment
samples obtained from the same patient clustered together
(Pt1, Pt2, Pt3, Pt5, Pt8, Supplementary Figure S1 online). This
indicates that lesions from each patient undergo similar
chemotherapy-induced changes, even if collected at different
time points. Multiple lesions from the same patient share
a median of 30% chemotherapy-specific gene probes.
Not one single gene was specifically and universally
modulated by chemotherapy in all the post-treatment
samples. However, we could identify genes commonly
modulated in a subset of samples. In particular, 366 gene
probes were affected by chemotherapy in at least 33% of the
samples analyzed (Figure 1a and Supplementary Table S1
online). On the basis of these genes, the most significant
biological processes specifically regulated by chemotherapy
are: cell cycle (Figure 1a, green cluster), epidermis develop-
ment (purple cluster), response to wounding and extracellular
matrix (ECM) organization (orange cluster), and immune
response (blue cluster). In particular, downregulation of cell
cycle-related genes and upregulation of the other clusters are
observed more frequently in cutaneous lesions sensitive to
DTIC (i.e., stable and regressing).
The chemotherapy-induced immune response cluster
included: (1) a lymphocyte signature with CD8A, CD2,
granzymes, the chemokine receptor CXCR3, the chemokine
CCL5, and molecules involved in lymphocyte activation
such as CD96, TNFRSF7, TNF, and RAC2 and (2) an antigen-
processing and presentation signature comprising several
major histocompatibility complex (MHC) class II molecules
and CD74 (Figure 1b).
To assess the extent of T-cell infiltration and to determine
which cells expressed human leukocyte antigen (HLA)-DR
after treatment, we performed immunohistochemistry for
CD8 and HLA-DR. Increased intra-tumoral CD8þ T-cell
infiltration was seen in several lesions after treatment,
including those from Pt5 and Pt3 (Figure 1c and Supple-
mentary Figure S2a online). Consistent with gene expression
results, CD8þ T cells also infiltrated the post-treatment lesion
from progressing Pt13 (not shown), although in this patient
the genes related to T-cell activation were not all upregulated
(Figure 1b). Before treatment, HLA-DR was expressed by
immune cells in peri-tumoral areas and by a small number of
macrophages/dendritic cells in the stroma (Figure 1c and
Supplementary Figure S2a online). In a few cases, focal
expression by tumor cells was also detected (Figure 1c, see
comparison with the melanoma-specific marker gp100). After
chemotherapy, HLA-DR upregulation was mainly due to
infiltration by (and presumably activation of) inflammatory
cells; however, increased expression by tumor cells was also
occasionally seen, e.g., in Pt5 (Figure 1c).
Thus, chemotherapy induces marked modifications in
melanoma metastases, with response to wounding, T-cell
infiltration, and immune activation commonly associated with
a decrease in cell cycle- and melanocyte-related processes.
Most melanoma lesions stabilized by chemotherapy activate
genetic programs related to ECM remodeling
The modulation of chemotherapy-specific probes clearly
distinguishes two groups of post-treatment lesions (Figure 1a),
one enriched in progressing tumors (left cluster) and the other
enriched within lesions that underwent either regression or
stabilization in response to treatment (right cluster, chemo-
sensitive). To formally define the genes differentially modu-
lated by chemotherapy in the two groups of patients, we used
only data from lesions that either progressed or stabilized
after treatment. The four regressing lesions from Pt1 and Pt2
were excluded from this analysis, as in these samples most
malignant tissue was substituted by normal tissue, as
indicated by both pathological examination and upregulation
of biological processes related to epidermis development
(Figure 1a).
A total of 60 gene probes were differentially modulated
between the two clusters of lesions defined in Figure 1a
(false discovery rate-corrected P-value o0.01, Figure 2a;
larger list of genes from P-value o0.05 is shown in
Supplementary Figure S3 online and in Supplementary Table
S2 online). The majority of chemotherapy-induced changes
in stable lesions corresponded to an increased expression of
genes associated with response to wounding, immune system
process, and ECM organization.
Among these 60 gene probes (Figure 2a), molecules like
secreted protein acidic and rich in cysteine (SPARC)
(osteonectin) and the related SPARCL1 and SMOC2, DCN
(decorin) and DPT (dermatopontin), FBLN1 and FBLN2
(fibulins), and MFAP4, are components of the ECM and are
involved in cell adhesion. We performed quantitative RT-PCR
to validate the microarray results on eight genes of this
signature, also including the chemokine CXCL12. PCR and
microarray gene expression data were correlated (Supple-
mentary Figure S4 online). ECM-related molecules were
commonly upregulated in responding (stable and regressing)
post-treatment lesions, whereas unchanged or downregulated
in progressing lesions (Figure 2b), confirming the results
obtained by microarray (Figure 2a). With the exception of
Figure 1. Chemotherapy specifically modulates the immune and stromal components of melanoma lesions. (a) Unsupervised hierarchical clustering of
366 probes regulated by chemotherapy in at least 33% of the post-treatment samples. The most significant GO processes for each cluster are indicated (complete
list of genes is available in Supplementary Table S1 online). Data are color-coded gene expression changes in post-treatment compared with pre-treatment
lesions. Array labels: P (red), progression; S (green), stable; R (blue), regression. (b) Subset of lymphocyte- and antigen presentation-related genes from
the blue cluster in a. (c) Representative immunohistochemistry staining for CD8, HLA-DR, and gp100 in lesions from patient Pt5; HLA, human leukocyte
antigen. Bar¼ 100 mm.
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FBLN1, the gene expression modulations in responding versus
progressing lesions were significantly different (Figure 2b).
SPARC was selected to further study the impact of treat-
ment, given its relevance in ECM organization and tumor
progression (Ledda et al., 1997; Alvarez et al., 2005; Robert
et al., 2006; Prada et al., 2007; Clark and Sage, 2008; Haber
et al., 2008; Chlenski and Cohn, 2010). Positive immuno-
histochemistry labeling for the SPARC protein was found in
fibroblasts, macrophages, endothelial cells, and tumor cells,
but not in lymphoid cells. In post-treatment lesions from Pt5
(Figure 2c) and in other stable lesions (Table 2, Figure 2d), we
observed a strong increase in the number of SPARC-positive
tumor cells, confirming the results obtained at the gene
expression level. On the other hand, SPARC expression was
Figure 2. Most melanoma lesions stabilized by chemotherapy activate genetic programs related to ECM remodeling. (a) Unsupervised hierarchical clustering
of 60 chemotherapy-specific probes modulated in at least 33% of lesions and differentially modulated in chemo-sensitive versus chemo-resistant lesions
(Mann–Whitney, Po0.01 on false discovery rate-corrected P-values). Labels and color coding are as in Figure 1. (b) Post-chemotherapy modulation of ECM-
related gene expression in responding versus non-responding lesions (qRT-PCR). Means±SD; P-values from Mann–Whitney. (c) Representative staining for
SPARC in stable (Pt5) and progressing (Pt7) post-treatment lesions. Bar¼ 100 mm. (d) Post-chemotherapy modulation of SPARC expression in tumor (left) and
stromal (right) cells in responding versus non-responding lesions. Values are from Table 2; P-values from Mann–Whitney. (e) Post-chemotherapy SPARC
modulation: correlation between gene and protein modulation in tumor. ECM, extracellular matrix; qRT-PCR, quantitative RT-PCR; SPARC, secreted protein
acidic and rich in cysteine.
Table 2. Quantification of SPARC expression in tumor and stromal cells from immunohistochemistry staining
Tumor cells Stromal cells1
Patient
code
Sample
code
Proportion
(%)
SPARC
positivity (%)
Change in SPARC
positivity (%)
Proportion
(%)
SPARC
positivity (%)
Change in
SPARC positivity (%)
Response
lesion
Pt1 Pre-1 80 15 20 90 NA
1-1 o10 ND2 ND 70 20 70 Regression
Pt2 Pre-2 80 40 20 80 NA
2-2 o10 ND ND 85 100 20 Regression
Pt3 Pre-3 80 60 20 60 NA
3-2 85 100 40 15 0 60 Stable
Pt4 Pre-4 80 35 20 90 NA
4-1 30 35 0 40 10 80 Progression
Pt5 Pre-5 90 10 o10 ND NA
5-1 80 90 80 20 90 ND Stable
Pt6 Pre-6 90 100 10 100 NA
6-1 50 100 0 30 30 70 Progression
Pt7 Pre-7 80 90 20 90 NA
7-1 85 70 20 15 15 75 Progression
Pt9 Pre-9 50 70 50 50 NA
9-1 60 80 10 40 30 20 Progression
Pt10 Pre-10 90 25 o10 ND NA
10-1 80 60 35 20 40 ND Stable
Pt11 Pre-11 85 35 15 80 NA
11-1 85 5 30 15 5 75 Progression
Pt12 Pre-12 90 10 10 10 NA
12-1 90 0 10 10 10 0 Progression
Pt13 Pre-13 15 100 85 100 NA
13-1 70 40 60 15 20 80 Progression
Abbreviations: NA, not applicable; ND, not determined; SPARC, secreted protein acidic and rich in cysteine.
Pt8 is missing because the pre-chemotherapy sample was not available.
1Stromal cells are fibroblastic cells and macrophages. Lymphocytes did not show any SPARC expression. Endothelial cells were always SPARC positive but
constituted o10% of the stroma.
2Not determined, cell population o10%.
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decreased after treatment in tumor cells from patient Pt7
(Figure 2c) and other progressing lesions (Table 2, Figure 2d).
In the stromal component (fibroblasts and macrophages),
SPARC expression was consistently decreased after chemo-
therapy, irrespective of the clinical response (Table 2,
Figure 2c and d). Of note, we found that gene and protein
modulations of SPARC expression within tumor are corre-
lated (Figure 2e).
Taken together, these results indicate that DTIC-sensitive
melanoma lesions, most of which undergo stabilization,
are commonly characterized by extensive ECM remodeling
and increased SPARC expression within the tumor cell
compartment.
Chemotherapy-induced stromal signatures are associated with
longer survival in melanoma patients
We next assessed whether the local effects of chemotherapy
were associated with longer patient survival. Such analyses
were difficult because of the limited number of patients,
advanced stage of disease, and low rate of objective res-
ponses to treatment. Despite this, we did detect a significantly
longer survival for patient with stage III disease at the time of
inclusion (Figure 3a), and patients who presented regression
or stabilization of at least one lesion during the course of
the study, i.e., Pt1, Pt2, Pt3, Pt5, Pt8, and Pt10 (Figure 3b).
Patients were also classified on the basis of the two
chemotherapy-specific signatures described above: increased
lymphocyte infiltration (found in Pt2, Pt3, Pt5, Pt8, and Pt13,
Figure 3c) or enhanced ECM remodeling (found in Pt1, Pt2,
Pt3, Pt4, Pt5, Pt8, and Pt10, Figure 3d). Longer survival
was associated with both signatures, particularly with
chemotherapy-induced ECM remodeling (P¼0.0014, hazard
ratio¼15, Figure 3d). Interestingly, ECM remodeling occurred
in all patients who were not only at stage III at the time of
inclusion but also in a subset of stage IV patients. In a
multivariate analysis including the factors stage and ECM
remodeling, the latter was the only significant factor contribut-
ing to survival (P¼0.0041, Supplementary Table S3 online).
In conclusion, chemotherapy-induced events leading to
ECM remodeling and lymphocyte infiltration in melanoma
metastases are associated with improved patient outcome.
DISCUSSION
To improve chemotherapy outcomes for the future, it is
critical that we first fully understand the mechanisms of
action of chemotherapeutic agents. This study identifies the
transcriptional response of patients’ melanoma lesions to
treatment with DTIC. Interestingly, different tumors from
the same patient shared an average of one-third of these
chemotherapy-specific gene changes, even when collected
several months apart. This result is consistent with recent
data indicating that individual metastasis in patients with
multifocal disease have similar gene expression patterns
(Augustine et al., 2010). It may also suggest that the impact
of chemotherapy is partly patient specific, i.e., determined by
systemic factors such as the immune response and the genetic
background of the patient and/or of the primary tumor.
It is likely that early changes induced by treatment are
predominantly characterized by DNA damage responses
and induction of apoptosis (Klopp et al., 2008). We chose to
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Figure 3. Patients with chemotherapy-induced signatures survive longer. Kaplan–Meier univariate survival analysis of melanoma patients: (a) stage III
or stage IV at the time of inclusion; (b) with or without at least one stable or responding lesion after treatment; (c) with or without increased lymphocyte
infiltration signature; (d) with or without increased ECM signature. P-values from log-rank (Mantel–Cox) test and hazard ratios are indicated. ECM, extracellular
matrix; HR, hazard ratio.
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analyze the impact of treatment at later time points, i.e., 2–4
weeks after the chemotherapy cycle, as late changes,
especially if immune-related, could be more relevant to
long-term clinical responses. It is not surprising that at later
time points a number of indirect effects of chemotherapy
were detected, including local stress events disruption of
homeostasis and wound healing. These events did not occur
in all post-treatment lesions, and thus clearly defined subsets
of chemo-sensitive and chemo-resistant tumors. For func-
tional analysis, we focused on gene probes regulated in at
least 33% of the lesions, as these genes are probably of
a broader significance for understanding the impact of
chemotherapy on melanoma.
Previous reports have described melanoma gene signa-
tures associated with patient survival (Mandruzzato et al.,
2006) or metastasis (Alonso et al., 2007). We found
a significant enrichment of chemotherapy-specific genes
within the group of survival-associated genes described by
Mandruzzato et al. (Supplementary Figure S5a online)
(P-value¼ 0.0001 by w2 test). On the other hand, several of
the metastasis-associated genes reported by Alonso et al.
were downregulated in chemo-sensitive tumors. Thus, treat-
ment-specific modulations in chemo-sensitive lesions are
consistent with a survival signature, but only partially
indicative of increased invasive potential. The chemo-
therapy-specific, survival-associated genes (Supplementary
Figure S5a online) are for the most part related to T cells,
lymphocyte activation, and MHC class II pathways, thus
mapping to the immune response cluster of Figure 1a.
Indeed, intra-tumoral lymphocyte activation, rather than
mere recruitment, has been formerly associated with superior
prognosis in primary melanoma (Hillen et al., 2008). These
results are also consistent with the previous observation of
increased tumor-infiltrating lymphocytes in breast cancers
following chemotherapy (Demaria et al., 2001).
MHC class II upregulation occurs in the same samples that
have a lymphocyte infiltration signature and markers of the
two events are correlated (Supplementary Figure S2b online).
We show here that these two observations are linked by
inflammatory cell recruitment (and possibly activation) and
by enhanced MHC expression on tumor cells. A previous
report describes upregulation of MHC class II in melanoma
tumors after treatment with a combination of cisplatin, DTIC
and IFN-a (Bernsen et al., 2003), and our results strongly
indicate that DTIC by itself may suffice to induce this event.
MHC class II expression by tumors has been frequently found
in melanoma, often in association with poor prognosis (Ruiter
et al., 1991). However, this association is not obvious in our
results.
Our analysis shows that DTIC can modulate genes related
to several ECM components (Figure 2a and b). In particular,
SPARC is one of the molecules upregulated within the ECM
signature characterizing chemo-sensitive tumors. SPARC is a
matricellular protein induced by disruption of tissue homeo-
stasis. It has been implicated in diverse roles related to
regulation of ECM structure and cell–matrix interaction,
inhibition of cell proliferation and angiogenesis, and inhibi-
tion of cell adhesion and epithelial–mesenchymal transition
(Clark and Sage, 2008; Chlenski and Cohn, 2010). Although
stromal cells can express SPARC, we detected upregulation
almost exclusively in tumor cells (Figure 2 and Table 2).
The role of SPARC in tumor progression varies with tumor
type and the cellular source of the protein; depending on the
context, SPARC can act as a suppressor or a promoter of
tumor progression (Clark and Sage, 2008; Chlenski and Cohn,
2010). In melanoma, tumor cell-derived SPARC has mostly
been implicated in increased tumorigenicity and metastasis
(Ledda et al., 1997; Massi et al., 1999; Alvarez et al., 2005;
Robert et al., 2006; Prada et al., 2007). On the basis of the
fact that melanoma tumor dissemination has been shown to
occur at an early stage in a mouse model (Eyles et al., 2010),
a metastatic phenotype may be of little clinical relevance in
advanced disease. In this situation, concomitant events
related to intrinsic or extrinsic (e.g., immune-mediated)
control of tumor growth could be instead effective in
prolonging survival.
Interestingly, our immunohistochemistry and gene expres-
sion data indicate that pre-treatment levels of SPARC are
lower in chemo-sensitive lesions (Figure 2 and Supplemen-
tary Figure S6 online). They also suggest that high expression
acquired during successive cycles of chemotherapy could
characterize the acquisition of resistance (see kinetics in
Supplementary Figure S6a online). Thus, SPARC and possibly
other genes in the ECM signature could be useful to predict
sensitivity to DTIC. The question of potential prognostic and
theranostic predictors could not be formally addressed in this
study because of the limited number of patients, but it will be
of relevance for future studies.
Chemotherapy treatment of late-stage melanoma induces
only 10–15% of objective clinical responses. In this study,
objective responses were observed only in stage III patients
with unresectable cutaneous metastases. We identified
chemotherapy-specific changes in the tumor microenviron-
ment of a subset of patients, including stage III and stage IV
patients. These changes are characteristic of chemotherapy-
sensitive lesions and often associated with local response.
With this knowledge, we can begin to understand the
interplay between established chemotherapeutics and the
patient’s own immune response.
MATERIALS AND METHODS
Patients and samples
Tumor samples were prospectively obtained from 13 stage III and IV
melanoma patients recruited at the Cochin Hospital (Paris, France)
between 2006 and 2009. The study was approved by the Ethics
Committee Ile de France. The Declaration of Helsinki protocols
were followed and patients gave their written, informed consent.
Inclusion criteria were stage III or stage IV unresectable melanoma,
no previous chemotherapy or immunotherapy, absence of brain
metastases, and presence of at least two cutaneous metastases as
targets for the study. Demographics and clinical characteristics
of patients are detailed in Table 1. Four patients had unresectable
stage III and nine had stage IV disease (M1a, M1b, or M1c). DTIC
was administered on 4 consecutive days at the daily dose of
250mg sqm1 every 28 days. Evaluation of visceral metastases by
brain, chest, and abdominal computed tomography scans was
www.jidonline.org 1903
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performed on days 0 and 56. In case of stabilization or response,
additional DTIC cycles were delivered. One cutaneous metastasis
was excised under local anesthesia before the start of the first DTIC
infusion, at the time of response evaluation (day 56), in case of
stabilization or response, or in case of cutaneous relapse. Half of the
sample was fixed for pathological confirmation and immuno-
histochemical studies, half was collected in RNALater (Qiagen,
Courtaboeuf, France) for gene expression analysis. Among stage III
patients, there were one complete response (Pt2), one partial
response (Pt1), one stabilization (Pt3), and one progression (Pt4).
Among stage IV patients, one patient had disease stabilization (Pt5),
and all others had progressive disease. However, in two of the latter,
the post-chemotherapy cutaneous metastases targeted for excision
had remained stable. Median survival was 6.5 months.
Gene expression microarrays
Total RNA was extracted using RNeasy kit (Qiagen) according to the
manufacturer’s instructions. The quality of total RNA was evaluated
using Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA);
only samples with RNA integrity number47.5 were analyzed. Gene
expression analysis was performed using Illumina Human-8 version
2 BeadChip arrays (Illumina, San Diego, CA). cRNA preparation,
purification and labeling, array hybridization, and scanning were
conducted as per the manufacturer’s instructions.
Array analysis: identification of genes specifically modulated
by chemotherapy
The primary objective of the analysis was to identify a list of
genes specifically modulated by DTIC treatment. To distinguish
chemotherapy-specific significances from inter-patient differences,
we created for each patient a multi-sample test including the pre-
chemotherapy and post-chemotherapy samples of that patient,
together with pre-chemotherapy samples from the other 12 patients.
For statistical analysis, the concept of the re-sampling-based
approach was used (Lunneborg, 1999). In a typical re-sampling-
based method, the shuffling step in the data is essential to give a
measure of randomness with respect to an observed significance.
However, in our test procedure, this shuffling step is not necessary as
the pre-chemotherapy samples of other patients are representative of
the randomness relative to the pre–post chemotherapy comparison.
For each patient, an analysis of variance test was run within the
multi-sample set-up. The q-values of the Dunnett test were then
computed for the patient’s post-chemotherapy samples and other
patients’ pre-chemotherapy samples against the patient’s pre-
chemotherapy sample as the control. The appropriate summary
statistics for the Dunnett tests were derived from the samples’
Illumina summary data based on the methodology discussed in the
study by Wong et al. (2008). For each pre–post chemotherapy
comparison, the number of times where the q-values of the pre–pre
comparison are larger than the pre–post was counted. This count was
further divided by the total number of pre–pre comparisons (n¼ 12).
The final value gives the probability of such an extreme result
(i.e., pre–post significance) under the null hypothesis and is known
as the re-sampled P-value, p. Furthermore, the expected fold-
change, fc of the pre–post chemotherapy comparison is given by
E(fc)¼ fc(1p). Gene probes with a re-sampled P-value, Po0.05,
and a |log2 fc|X0.5 were considered specifically modulated by
chemotherapy treatment.
In silico biological and functional analyses
Unsupervised hierarchical clustering and differential expression
analysis were performed using Partek Genomics Suite (Partek,
St Louis, MO). For unsupervised hierarchical clustering, genes were
clustered based on Spearman’s correlation and arrays based on
Euclidian distance. Genes differentially modulated by chemotherapy
between groups of patients were identified using a Mann–Whitney test,
followed by a multiple test correction using the Benjamini–Hochberg
algorithm. Gene Ontology process analysis was performed using
MetaCore (GeneGo, St Joseph, MI). Gene lists associated with
melanoma patient survival or metastasis were obtained from published
data (Mandruzzato et al. (2006) and Alonso et al. (2007), respectively).
Quantitative RT-PCR
RNA from 28 available samples was converted to cDNA using the
Taqman Reverse Transcriptase reagents with the ABI Thermocycler
2720 (Applied Biosystems, Foster City, CA). Primers were designed
using Primer3 (Supplementary Table S4 online). Quantitative PCR
was performed on cDNA using iTaq SYBR Green Supermix with
ROX (Bio-Rad Laboratories, Hercules, CA) with Mx3000P QPCR
system and MxPro software (Stratagene, La Jolla, CA). Relative gene
expression levels were calculated by normalization to actin beta.
Immunohistochemistry
Paraffin-embedded tumor sections from 13 patients were analyzed.
Sections of 4-mm thickness from formalin-fixed paraffin-embedded
tissues were mounted on Superfrost/Plus glass slides. The paraffin
was eliminated by incubating the sections in xylene and then
rehydrating. For antigen retrieval, sections were heated in Bond
Epitope Retrieval Solution 1 (Menarini Diagnostic, Florence, Italy)
for 20minutes at 99 1C in pH 6.0 10mmol sodium citrate buffer
(for CD8, gp100, HLA-DR staining) or in Bond Epitope Retrieval
Solution 2 (Menarini Diagnostic) for 20minutes at 99 1C in pH 9.0
10mmol sodium citrate buffer (for SPARC staining). The slides were
incubated with anti-SPARC (Novocastra NCL-O-NECTIN, clone
15G12, Menarini Diagnostic), anti-HLA-DR (clone TAL.1B5, Dako,
Trappes, France), anti-gp100 (clone HMB-45, Dako), or anti-CD8
(Novocastra NCL-L-CD8-295, Menarini Diagnostic) antibodies for
20minutes at 99 1C. The labeling was detected with the Bond Polymer
Refine Detection kit (Menarini Diagnostic). Photos were taken at
 100 magnification using a Leica DMR microscope and DC300F
camera (Leica, Solms, Germany). The proportion of cell types and
their expression of SPARC were estimated visually by a pathologist.
Survival analysis
Both univariate (Kaplan–Meier, GraphPad Prism, GraphPad, La Jolla, CA)
and multivariate (Cox proportional-hazards regression model Forward
method with ‘‘Stage’’ and ‘‘ECM response’’ factors, MedCalc, Mariakerke,
Belgium) analysis were performed. Pt3 (survival 445 months) and Pt2
(cause of death other than melanoma) were censored.
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